Publications by authors named "M Chrapava"

Claim this Profile
R
Real-world PD-L1 testing, fi rst-line therapy for advanced NSCLC, and fi rst-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic.
M L Santorelli, M Chrápavá, K Hrabcová, G Bencina, J Blažek

Klin Onkol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Marika Chrapava

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Marika Chrapava

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe.
Fruzsina Kósa, Tereza Nečasová, Martin Špaček, Krzysztof Giannopoulos, Iwona Hus

Cancer Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
Matti Aapro, Zoe Caprariu, Petio Chilingirov, Marika Chrápavá, Razvan-Ovidiu Curca

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis